Combination treatment for untreated large b-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug combo for people with an aggressive type of large b-cell lymphoma. It aims to see if adding the new drug to standard chemo plus an antibody therapy is safe and works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have newly diagnosed large b-cell lymphoma that is CD20-positive (a marker on the cancer cells) and not in the brain or spinal cord.
- Your lymphoma must have high levels of BCL-2 or have double-hit features (extra genes in the cancer cells).
- You must have not had any prior cancer treatment for this lymphoma, except steroids.
- You need a certain level of general health, with a score of 0 to 2 on the ECOG scale (you are up and about, at least partially).
- You must have at least one measurable tumor on a scan (a lymph node larger than 1.5 cm or a tumor outside the lymph nodes larger than 1 cm).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs for people with large b-cell lymphoma that has come back or not responded to the first treatment. It aims to see if this combination can help control the cancer and prepare for a type of cell therapy called liso-cel.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
This study tests whether a computer-guided treatment plan can work as well as or better than the standard chemo-immunotherapy for large B-cell lymphoma. It uses a special test after the first cycle to decide who needs a more aggressive approach.
This study tests a new combination of four drugs—sonrotoclax, glofitamab, gemcitabine, and oxaliplatin—in people with large B-cell lymphoma that has come back or not responded to earlier treatment. The goal is to see if this combination can shrink or control the lymphoma.
This study tests whether a new three-drug combination (Pola-ZR-Glo) works safely and effectively for older adults with a type of blood cancer called large B-cell lymphoma who cannot or prefer not to receive standard chemotherapy. The goal is to find a gentler treatment option for frail or elderly patients.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.